Frequently Asked Questions
The market is segmented based on , By Therapy (Testosterone Replacement Therapy, Estrogen Therapy, and Progesterone Therapy), Drug Delivery (Topical Gels, Injectable, Transdermal Patches, and Others), Type (Hypergonadotropic Hypogonadism and Hypogonadotropic Hypogonadism), Route of Administration (Oral, Injectable, Transdermal Patch, Implantable Pellet, and Tropical), End-Users (Hospitals, Homecare, Specialty Clinics, and Others) – Industry Trends and Forecast to 2031.
.
The Global Hypogonadism Drug Market size was valued at USD 9.50 USD Billion in 2023.
The Global Hypogonadism Drug Market is projected to grow at a CAGR of 4% during the forecast period of 2024 to 2031.
The major players operating in the market include AbbVie inc. (U.S.), Bausch Health Companies Inc. (Canada), Sun Pharmaceutical Industries Ltd. (India), Hikma Pharmaceuticals PLC (Japan), Amneal Pharmaceuticals LLC. (U.S.), Alvogen (U.S), Teva Pharmaceutical Industries Ltd (Israel), Endo Pharmaceuticals plc (Ireland), Perrigo Company plc (U.S.), Johnson & Johnson Services, Inc (U.S.), Ferring B.V. (Switzerland), Antares Pharma (U.S.), Aytu BioPharma, Inc. (U.S.), and HYUNDAIPHARM. Co. Ltd (South Korea).
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
